Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511095 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
A Phase 2 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
NCT00511095 is a Phase 2 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 207 participants.
The verdict
NCT00511095, a Phase 2 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
Study Summary
The purpose of this study is to further evaluate the safety and seroprotective immune response of a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, in subjects 11-55 years old. The primary hypothesis is that HEPLISAV™ is well tolerated.
Interventions
- BIOLOGICAL HEPLISAV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511095
The ClinicalTrials.gov registry entry for NCT00511095 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HEPLISAV is the first listed.
NCT00511095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511095 about?
NCT00511095 is a clinical study titled "Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine". The purpose of this study is to further evaluate the safety and seroprotective immune response of a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, in subjects 11-55 years old. The primary hypothesis is that HEPLISAV™ is well tolerated.
What is the current status of trial NCT00511095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2007-06. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00511095?
The interventions under investigation include: HEPLISAV (BIOLOGICAL).
Who is sponsoring clinical trial NCT00511095?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.